Regentis Advances GelrinC® for Knee Cartilage Repair, Targeting $3B Market

Regentis Biomaterials Ltd. (NYSE American: RGNT) is making significant strides in knee cartilage repair with its innovative cell-free hydrogel implant, GelrinC®. The company is targeting a $3 billion U.S. market that sees approximately 470,000 annual knee cartilage repair cases, where currently no approved off-the-shelf regenerative solution exists. GelrinC® is designed to simplify the repair process through a single-step, approximately 10-minute procedure, offering an alternative to traditional microfracture and complex cell-based therapies. Clinical data have shown approximately 100% greater pain improvement versus microfracture, along with MRI-confirmed regeneration of near-native cartilage and durable multi-year outcomes. The product has already secured CE Mark approval in Europe and is progressing through a pivotal U.S. Phase III trial that is more than 50% enrolled. This positions Regentis for several upcoming catalysts, including potential European commercialization, completion of the pivotal study, and eventual FDA submission.

Regentis Biomaterials is a regenerative medicine company focused on developing innovative tissue repair solutions. Its Gelrin platform technology utilizes synchronized, degradable hydrogel implants to regenerate damaged or diseased tissue, including inflamed cartilage and bone. GelrinC® is a cell-free, off-the-shelf hydrogel that is eroded and resorbed in the knee, allowing surrounding cells to regenerate cartilage in a controlled and synchronous process. The company aims to address a significant unmet need in the orthopedic market, where no off-the-shelf treatment is available for the large number of cartilage repair cases. For more details, a full corporate profile is available at https://ibn.fm/bpPp6.